Urigen Pharmaceuticals, Inc. Sustainability Profile
Urigen Pharmaceuticals, Inc., a leading player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in developing innovative therapies for urological conditions, focusing on unmet medical needs. With a strong presence in the US and expanding operations in key international markets, Urigen is dedicated to advancing patient care through its unique product offerings. The company’s flagship product, a proprietary formulation for the treatment of bladder pain syndrome, stands out for its targeted approach and efficacy. Recognised for its commitment to research and development, Urigen Pharmaceuticals has established a solid market position, contributing to advancements in urology and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Urigen Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Urigen Pharmaceuticals, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Urigen Pharmaceuticals, Inc.'s reported carbon emissions
Urigen Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Urigen Pharmaceuticals may not yet have established a formal strategy for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Urigen to consider developing and communicating its climate commitments in the future.
How Carbon Intensive is Urigen Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Urigen Pharmaceuticals, Inc.'s Location?
Urigen Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Urigen Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
